专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020049001A1 NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF 审中-公开
公开(公告)号：WO2020049001A1
公开(公告)日：2020-03-12
申请号：PCT/EP2019/073488
申请日：2019-09-03
申请人： BIOINVENT INTERNATIONAL AB , TRANSGENE SA
发明人： FRENDÉUS, Björn , TEIGE, Ingrid , SEMMRICH, Monika , MÅRTENSSON, Linda , HOLMKVIST, Petra , MARCHAND, Jean-Baptiste , SILVESTRE, Nathalie
IPC分类号： C07K16/28 , A61P37/02 , A61P35/00
摘要： Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.

2. 发明申请

WO2023046777A1 NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2023046777A1
公开(公告)日：2023-03-30
申请号：PCT/EP2022/076268
申请日：2022-09-21
申请人： BIOINVENT INTERNATIONAL AB , TRANSGENE SA
发明人： FRENDÉUS, Björn , REHN, Mathilda , SEMMRICH, Monika , MÅRTENSSON, Linda , MARCHAND, Jean-Baptiste
IPC分类号： A61P35/00 , C07K16/28 , A61K39/00
摘要： The present invention generally relates to a combination of an oncolytic virus capable of expressing a first antibody molecule that specifically binds to CTLA-4; and a second antibody molecule that specifically binds to PD-1 and/or PD-L1 and uses thereof in the treatment of cancer.

3. 发明申请

WO2023046777A8 NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2023046777A8
公开(公告)日：2023-03-30
申请号：PCT/EP2022/076268
申请日：2022-09-21
申请人： BIOINVENT INTERNATIONAL AB , TRANSGENE SA
发明人： FRENDÉUS, Björn , REHN, Matilda , SEMMRICH, Monika , MÅRTENSSON, Linda , MARCHAND, Jean-Baptiste
IPC分类号： A61P35/00 , C07K16/28 , A61K39/00 , A61K2039/505 , A61K2039/507 , A61K2039/5256 , C07K16/2818 , C07K16/2827 , C12N2710/24132 , C12N2710/24143
摘要： The present invention generally relates to a combination of an oncolytic virus capable of expressing a first antibody molecule that specifically binds to CTLA-4; and a second antibody molecule that specifically binds to PD-1 and/or PD-L1 and uses thereof in the treatment of cancer.

5. 发明公开

EP3847193A1 NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF 审中-实审
公开(公告)号：EP3847193A1
公开(公告)日：2021-07-14
申请号：EP19761869.7
申请日：2019-09-03
申请人： BioInvent International AB , TRANSGENE S.A.
发明人： FRENDÉUS, Björn , TEIGE, Ingrid , SEMMRICH, Monika , MÅRTENSSON, Linda , HOLMKVIST, Petra , MARCHAND, Jean-Baptiste , SILVESTRE, Nathalie
IPC分类号： C07K16/28 , A61P37/02 , A61P35/00

6. 发明申请

WO2018234506A2 PERSONALIZED VACCINE 审中-公开
公开(公告)号：WO2018234506A2
公开(公告)日：2018-12-27
申请号：PCT/EP2018/066668
申请日：2018-06-21
申请人： TRANSGENE SA
发明人： BENDJAMA, Kaïdre , SILVESTRE, Nathalie , MARCHAND, Jean-Baptiste , GRELLIER, Benoît
IPC分类号： A61K39/00 , A61P35/00 , C12N7/00
摘要： The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy, specifically for stimulating T cell immune response.

7. 发明申请

WO2020136232A1 IMMUNOSUPPRESSIVE M2 PROTEIN 审中-公开
公开(公告)号：WO2020136232A1
公开(公告)日：2020-07-02
申请号：PCT/EP2019/087059
申请日：2019-12-27
申请人： TRANSGENE SA
发明人： KLEINPETER, Patricia , MARCHAND, Jean-Baptiste , REMY, Christelle
IPC分类号： C12N15/86 , A61K39/00
摘要： The invention is in the field of immunity and provides a poxviral polypeptide (referred here as M2 polypeptide) having the ability to bind B7-1 (CD80) and B7-2 (CD86) costimulatory molecules and modify their interactions with T cell surface receptors CD28, CTLA4 (for cytotoxic T-lymphocyte–associated antigen 4) and/or PD-L1(for programmed death-ligand 1). The present invention also relates to vector for expression of said poxviral M2 polypeptide and composition comprising said M2 polypeptide or expression vector for use as a new immunosuppressive drug as well as methods for treating diseases or disorders associated with non-adequate immune responses such as autoimmune diseases andtransplant rejections that comprise the administration of such a M2 polypeptide, M2-expressing vector or composition thereof (active agent). The present invention also relates to methods for producing such a M2 polypeptide.

8. 发明申请

WO2015104380A1 FUSION OF HETEROOLIGOMERIC MYCOBACTERIAL ANTIGENS 审中-公开
标题翻译：异氟烷抗体的融合
公开(公告)号：WO2015104380A1
公开(公告)日：2015-07-16
申请号：PCT/EP2015/050344
申请日：2015-01-09
申请人： TRANSGENE SA
发明人： MARCHAND, Jean-Baptiste , SILVESTRE, Nathalie , PENIN, François
IPC分类号： A61K39/04 , C07K16/12
CPC分类号： A61K39/04 , A61K45/06 , A61K2039/5256 , A61K2039/53 , A61K2039/57 , C07K14/35 , C07K16/1289 , C07K2317/34 , C07K2319/00 , C07K2319/035 , C12N2710/24141
摘要： The present invention relates generally to novel immunogenic combinations comprising or encoding at least two heterooligomeric mycobacterial antigens and preferably a fusion polypeptide comprising said two heterooligomeric mycobacterial antigens, where the mycobacterial antigens are selected from the group of Esx, PE and PPE antigens of a Mycobacterium species, particularly a Mycobacterium of the tuberculosis complex such as Mycobacterium tuberculosis (Mtb). The present invention also relates to vectors, host cells and compositions comprising or encoding said immunogenic combination as well as to methods for expressing and producing it. The present invention also relates to methods of using said immunogenic combination, fusion polypeptide, vector, host cell, composition particularly for inducing or stimulating an immune response with the goal of providing a protective response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.
摘要翻译：本发明一般涉及包含或编码至少两种异寡分子分枝杆菌抗原的新型免疫原性组合，优选包含所述两种异源寡分支分枝杆菌抗原的融合多肽，其中分枝杆菌抗原选自分枝杆菌属物种的Esx，PE和PPE抗原，特别是结核分枝杆菌复合物如结核分枝杆菌（Mtb）的分枝杆菌。本发明还涉及包含或编码所述免疫原性组合的载体，宿主细胞和组合物以及用于表达和产生它的方法。本发明还涉及使用所述免疫原性组合，融合多肽，载体，宿主细胞，组合物特别用于诱导或刺激免疫应答的方法，其目的是提供针对分枝杆菌感染的保护性应答或由分枝杆菌感染。

9. 发明申请

WO2012110360A1 ANTIBODY AGAINST THE CSF-1R 审中-公开
标题翻译：抗CSF-1R抗体
公开(公告)号：WO2012110360A1
公开(公告)日：2012-08-23
申请号：PCT/EP2012/052043
申请日：2012-02-07
申请人： TRANSGENE SA , HAEGEL, Hélène , THIOUDELLET, Christine , GEIST, Michel , GRELLIER, Benoît , MARCHAND, Jean-Baptiste
发明人： HAEGEL, Hélène , THIOUDELLET, Christine , GEIST, Michel , GRELLIER, Benoît , MARCHAND, Jean-Baptiste
IPC分类号： C07K16/28 , A61P35/00 , A61P37/00 , C12N15/13 , C12N15/63
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C12N15/11 , C12N15/62 , C12N2740/15043
摘要： The present invention provides antibodies specific for the CSF-1 R, compositions comprising said antibodies and methods of treatment using such compositions.
摘要翻译：本发明提供对CSF-1R具有特异性的抗体，包含所述抗体的组合物和使用这些组合物的治疗方法。

10. 发明申请

WO2018234506A3 PERSONALIZED VACCINE 审中-公开
公开(公告)号：WO2018234506A3
公开(公告)日：2018-12-27
申请号：PCT/EP2018/066668
申请日：2018-06-21
申请人： TRANSGENE SA
发明人： BENDJAMA, Kaïdre , SILVESTRE, Nathalie , MARCHAND, Jean-Baptiste , GRELLIER, Benoît
IPC分类号： A61K39/00 , A61P35/00 , C12N7/00
摘要： The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy, specifically for stimulating T cell immune response.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式